Edition:
United Kingdom

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

681.00INR
11:12am BST
Change (% chg)

Rs0.50 (+0.07%)
Prev Close
Rs680.50
Open
Rs679.50
Day's High
Rs689.80
Day's Low
Rs676.00
Volume
760,703
Avg. Vol
1,092,751
52-wk High
Rs711.90
52-wk Low
Rs493.50

Select another date:

Mon, May 21 2018

BRIEF-Glenmark Pharmaceuticals Submitts NDA To U.S. FDA For Ryaltris

* GLENMARK PHARMACEUTICALS - SUBMITTED NDA TO U.S. FDA FOR LEADING RESPIRATORY PIPELINE CANDIDATE RYALTRIS Source text for Eikon: Further company coverage:

BRIEF-Glenmark Pharma Says Co Suspended Trial Conducted at Malpani Hospital After Alleged Irregularities

* CLARIFIES ON NEWS ITEM ABOUT CO GETTING NOTICE OVER MISCONDUCT IN CLINICAL TRIALS

BRIEF-Glenmark Pharmaceuticals Gets ANDA Approval For Clobetasol Propionate Topical Solution USP

* GETS ANDA APPROVAL FOR CLOBETASOL PROPIONATE TOPICAL SOLUTION USP

BRIEF-Glenmark Pharmaceuticals Gets ANDA Approval For Tacrolimus Ointment, 0.1 Pct

* SAYS CO GETS ANDA APPROVAL FOR TACROLIMUS OINTMENT, 0.1 PERCENT Source text - http://bit.ly/2HKxf5K Further company coverage:

BRIEF-Glenmark Pharmaceuticals, Helsinn Group Enter Into Agreement For Launch Of Akynzeo In India And Nepal

* SAYS CO, HELSINN GROUP ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR LAUNCH OF AKYNZEO IN INDIA AND NEPAL

BRIEF-Glenmark Pharmaceuticals Gets ANDA Approval From U.S. FDA For Clobetasol Propionate Spray, 0.05 Pct

* SAYS ‍CO GETS ANDA APPROVAL FROM U.S. FDA FOR CLOBETASOL PROPIONATE SPRAY, 0.05 PERCENT

Select another date: